Individuelle Verlaufskontrolle der TSHRezeptor- Antikörper-Titer zur Einschätzung der Prognose eines M. Basedow
暂无分享,去创建一个
T. Rink | H. Garth | H. Schroth | L. Holle
[1] I. Chiodini,et al. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence? , 1996, Clinical endocrinology.
[2] M. Baldini,et al. Color Doppler sonography in Graves' disease: value in assessing activity of disease and predicting outcome. , 1996, AJR. American journal of roentgenology.
[3] H. Gao,et al. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease]. , 1994, Zhonghua yi xue za zhi.
[4] J. Wemeau. [Are there prognostic markers of recovery after antithyroid drugs?]. , 1994, Annales d'endocrinologie.
[5] P. Carayon,et al. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. , 1994, The Journal of clinical endocrinology and metabolism.
[6] Hong-Kyu Lee,et al. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease , 1992, Clinical endocrinology.
[7] L Chiovato,et al. Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves' disease. , 1992, Acta endocrinologica.
[8] T. Yamada. [TSH receptor antibody in hyperthyroid patients due to Graves' disease treated with antithyroid drugs]. , 1991, Nihon Naibunpi Gakkai zasshi.
[9] M. Fujishima,et al. Prediction of relapse in drug-treated Graves' disease using thyroid stimulation indices. , 1991, Acta endocrinologica.
[10] B. Bravenboer,et al. Logistic multiple regression analysis of factors predicting recurrence of hyperthyroidism after medical treatment of toxic diffuse goitre. , 1991, The Netherlands journal of medicine.
[11] S. Gong,et al. Changes in serum thyroglobulin and thyroid autoantibodies in patients with Graves' disease treated with antithyroid drug and their relationship to relapse. , 1991, Journal of the Formosan Medical Association = Taiwan yi zhi.
[12] S. Ratanachaiyavong,et al. DQA2 U ALLELE: A GENETIC MARKER FOR RELAPSE OF Graves'DISEASE , 1990, Clinical endocrinology.
[13] B. Glaser,et al. THYROTROPHIN RECEPTOR BLOCKING ANTIBODIES: INCIDENCE, CHARACTERIZATION AND IN‐VITRO SYNTHESIS , 1987, Clinical endocrinology.
[14] E. Krenning,et al. CELLULAR AND HUMORAL IMMUNITY IN PATIENTS WITH HYPERTHYROID GRAVES' DISEASE BEFORE, DURING AND AFTER ANTITHYROID DRUG TREATMENT , 1987, Clinical endocrinology.
[15] H. Drexhage,et al. Thyroid antibodies in thyroid diseases. , 2008, Ciba Foundation symposium.
[16] I. Hales,et al. Thyroid stimulating immunoglobulin in Graves' disease. , 1981, Australian and New Zealand journal of medicine.
[17] K. Hashizume,et al. Changes in thyroid-stimulating immunoglobulins during antithyroid therapy. , 1979, The Journal of clinical endocrinology and metabolism.
[18] R. Finke,et al. Relationship between thyroid status and Graves' disease-specific immunoglobulins. , 1978, The Journal of clinical endocrinology and metabolism.
[19] R. Finke,et al. Determination of thyroid stimulating immunoglobulins (TSI) during the course of Graves’ disease. A reliable indicator for remission and persistence of this disease? , 1978, Journal of endocrinological investigation.
[20] D. Evered,et al. Thyroid-stimulating immunoglobulins and the control of thyroid function. , 1976, The Journal of clinical endocrinology and metabolism.